Over the last year, the health care sector has generated a positive performance and analysts predict that the numbers should only continue to improve. Most companies throughout the sector have strong balance sheets while their stocks are offering pleasant dividends to their investors. Elevated demand for health care services and products due to an aging population which calls for more wide-ranging drug treatments and medical care is certainly another factor driving the sector.
One more aspect to consider pushing the sector is the Feds continue to hike up rates and the sector, on average since 1970, has outperformed during Fed hiking cycles, according to BCA research. Investors continue to flock to the healthcare sector in times of uncertainty in the general market as sort of a haven as it remains consistent throughout all economic conditions.
As demand increases for more extensive care and treatments for the aging population, healthcare companies are working around the clock to get their products approved. What the anticipation of, or approval of a product can do for a share price is another factor that continues to appeal to investors.
GT Biopharma (GTBP), a clinical stage bio-pharmaceutical company, recently announced that a Material Transfer Agreement between a Major Pharmaceutical Company and Dr. Daniel Vallera, GTBP’s lead researcher, has been made. Under the terms of the agreement, this Company will supply a formulation of their multibillion-dollar oncology drug, which has been approved for use in several hematologic malignancies, for use in the study. Initial pre-clinical work performed by Dr. Vallera suggests an enhanced effect when OXS-1550 is given in combination with this widely prescribed oncology drug.
Tandem Diabetes Care, Inc. (TNDM), a medical device company, recently announced via press release the launch of the t:slim X2 Insulin Pump with Basal-IQ Technology. The device is a predictive low glucose suspend feature designed to assist with the reduction of hypoglycemia frequency as well as duration. The device is combined with the Dexcom G6 CGM System, that doesn’t not require the use of finger sticks for calibration.
Exact Sciences Corp. (EXAS) is a molecular diagnostics company which focuses on the development of products for the early detection and prevention of different types of cancer. The company had announced an agreement yesterday to co-market Cologuard with Pfizer (PZE) for the next four years. Colorguard is the first and only FDA-approved non-invasive stool DNA screening test for colorectal cancer.
Rexahn Pharmaceuticals, Inc. (RNN), clinical stage bio-pharmaceutical company, recently announced a clinical trial collaboration agreement with Merck (MRK) to evaluate the combination of Rexahn’s RX-5902 and Merck’s anti-PD-1 therapy, KEYTRUDA® in a Phase 2 trial in patients with metastatic triple negative breast cancer (TNBC). Under the terms of the agreement, Rexahn will sponsor the RX-5902 and KEYTRUDA study.
MIDAM VENTURES LLC., a Florida Corporation has been compensated $200,000.00 by GT Biopharma Inc. for a period beginning July 16, 2018 and ending August 16, 2018 to publicly disseminate information about (GTBP). Midam owns zero shares. Midam may buy or sell additional shares of (GTBP) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.